Entos Enters Research and Collaboration with Lilly for Non-Viral Vectors for Multiple Neurologic Indications
January 6, 2022
Eli Lilly has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to research, develop, and commercialize nucleic acid products targeting the central and peripheral nervous system, the companies said.
The technology provides an opportunity for Lilly to access a novel delivery platform technology with the potential to solve a key delivery challenge for many nucleic acid therapeutic modalities.
Under the terms of the research and collaboration agreement, Lilly and Entos have agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo supplied by Lilly to targets in the central and peripheral nervous systems.
Entos will be responsible for the generation, development and optimization of PLVs using its proprietary Fusogenix platform technology. Lilly will be responsible for selecting PLVs for clinical development and commercialization.
Entos will receive an initial payment of $50 million, which includes an equity investment by Lilly in Entos. For each of the programs under the collaboration, Entos is also eligible to receive up to $400 million in potential developmental and commercial milestone payments, as well as royalties upon the successful development and commercialization of products.
“Nucleic acid-based therapies hold great promise in addressing the biologic cause of many serious diseases that have significant unmet medical need,” said Andrew Adams, vice president, Lilly Genetic Medicine. “Overcoming barriers to the safe and effective delivery of such therapies to specific target cells is essential to realizing their potential.”
Author: Rare Daily Staff
Sign up for updates straight to your inbox.